AN2 Net Interest Income from 2010 to 2024

ANTX Stock  USD 1.67  0.30  21.90%   
AN2 Therapeutics Net Interest Income yearly trend continues to be fairly stable with very little volatility. Net Interest Income is likely to outpace its year average in 2024. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
First Reported
2010-12-31
Previous Quarter
1.6 M
Current Value
1.6 M
Quarterly Volatility
625.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AN2 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AN2 Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 73.1 M, Interest Expense of 620.7 K or Selling General Administrative of 7.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.68. AN2 financial statements analysis is a perfect complement when working with AN2 Therapeutics Valuation or Volatility modules.
  
Check out the analysis of AN2 Therapeutics Correlation against competitors.
For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

Latest AN2 Therapeutics' Net Interest Income Growth Pattern

Below is the plot of the Net Interest Income of AN2 Therapeutics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. AN2 Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AN2 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Interest Income10 Years Trend
Slightly volatile
   Net Interest Income   
       Timeline  

AN2 Net Interest Income Regression Statistics

Arithmetic Mean309,199
Geometric Mean12,827
Coefficient Of Variation202.18
Mean Deviation481,118
Median3,000
Standard Deviation625,133
Sample Variance390.8B
Range1.6M
R-Value0.71
Mean Square Error210B
R-Squared0.50
Significance0
Slope98,951
Total Sum of Squares5.5T

AN2 Net Interest Income History

20241.6 M
20231.6 M
20221.4 M
202169 K

About AN2 Therapeutics Financial Statements

AN2 Therapeutics investors use historical fundamental indicators, such as AN2 Therapeutics' Net Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AN2 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Interest Income1.6 M1.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.